We are a group company of SCREEN Holdings Co., Ltd.

MED64-Basic System is user-friendly microelectrode array (MEA) system for in vitro extracellular electrophysiology. It features with the industry's most sensitive MEA system, providing high-quality reliable data. Created by Panasonic, the MED64 has been on market for 20 years and has hundreds of users and publications worldwide.


MED64-Quad II system is a medium throughput MEA system both for acute and cultured applications. Extracellular signals are recorded from 4 independent Probes/Connectors, which will give high flexibility. It is a powerful solution for drug discovery screening. The MED64's high fidelity will provide more accurate and reliable data allowing for advanced screening.


MED64-Allegro System is a medium throughput MEA system for cultured applications. It is an ideal solution for drug testing using stem cell-derived cardiomyocytes or/and neurons. The MED64's high fidelity will provide more accurate and reliable data allowing advanced screening as well as analysis during the testing.


MED64-Plex 4/8 System is a medium throughput MEA system allowing recording at all 64 electrodes from 4 or 8 samples. The MED64’s high fidelity will provide more accurate and reliable data allowing advanced screening.


The MED64 Presto is a microelectrode array (MEA) system that incorporates the industry leading sensitivity of the MED64 platform in an easy to use multi-well format. Modern, intuitive, easy to use software makes data collection and analysis effortless.
The MED64 Presto is engineered for researchers who need the correct answer to their scientific inquiries and reveals data that can be missed by other platforms.


The entry model of MED64 System consisting of 16-channel amplifier. Acquires extracellular potential from predetermined 16 out of 64 electrodes patterned on MED Probe.


We are a group company of SCREEN Holdings Co., Ltd.
